Latest messages for CancerCompass discussion http://www.cancercompass.com/message-board/message/all,36863,0.htm Mon, 23 Nov 2009 00:00:00 GMT Mon, 23 Nov 2009 00:00:00 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ While there is no patent on the drug RU486 (mifepristone), clinical trials may be slow, however, it is available for individual patient use via the Compassionate Use Program (in the US) and TGA (in Aust) for those for whom standard therapies have failed. Might be worth noting if you've exhausted all options. 2003: Enhancement of antitumor effect of cisplatin against human ovarian carcinoma cells by mifepristone in vivo.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&a “At a non-toxic dose, RU486 may enhance the sensitivity of tumor cells to cisplatin in vivo, possibly through the mechanism of inhibiting GcS expression at the mRNA level.” 2007: Synergistic effects of mifepristone on the cytotoxicity of cisplatin in cervical carcinoma cell lines and tumors grown in athymic micehttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=17  “Analysis of the data by the isobologram method shows that the combination of mifepristone and cisplatin produced a synergistic effect in cervical cancer cells. The effect of mifepristone on the cytotoxicity of cisplatin could be mediated, at least partially, by increase of intracellular cisplatin accumulation and the down-regulation of the Bcl-2 expression. The in vivo studies showed that the combination of these agents had a significant antitumor activity against xenograft tumors.Our results suggest that mifepristone can improve the efficacy of cisplatin in cancer cells and this anti-hormonal drug therapy may be a candidate for further evaluation in combination with antineoplastic drugs in the treatment of cancer.” Gal49 Sat, 06 Jun 2009 00:00:00 GMT